Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in Severe COVID-19 Pneumonia
jRCT1080225320Phase 1Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by Rohto Pharmaceutical Co., Ltd. Started Aug 2020; status: completed.
02
Drugs
ADR-001
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on jRCT1080225320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225320.